 |
 |
Sensipar Amgen Inc. - Treatment for Secondary Hyperparathyroidism in dialysis patients
Sensipar is a first-in-class oral calcimimetic indicated for the treatment of secondary hyperparathyroidism (secondary HPT) in chronic kidney disease (CKD) patients on dialysis, and the treatment of elevated calcium levels (hypercalcemia) in patients with parathyroid carcinoma.Posted: March 2004
Drugs.com provides accurate and independent information on more than 24,000 prescription drugs, over-the-counter medicines and natural products. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment.
Data sources include Micromedex™ (updated Apr 24th, 2013), Cerner Multum™ (updated Apr 19th, 2013), Wolters Kluwer™ (updated Apr 30th, 2013) and others. To view content sources and attributions, refer to our editorial policy.
Copyright © 2000-2013 Drugs.com. All rights reserved.
We comply with the HONcode standard for trustworthy health information.
Verify here
